TITLE

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

AUTHOR(S)
McDonnell, David P.; Detke, Holland C.; Bergstrom, Richard F.; Kothare, Prajakti; Johnson, Jason; Stickelmeyer, Mary; Sanchez-Felix, Manuel V.; Sorsaburu, Sebastian; Mitchell, Malcolm I.
PUB. DATE
January 2010
SOURCE
BMC Psychiatry;2010, Vol. 10, p45
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. Methods: Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media. Results: Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue. Conclusions: Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS. Trial Registration: ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/: NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489
ACCESSION #
52838983

 

Related Articles

  • Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. Detke, Holland C.; McDonnell, David P.; Brunner, Elizabeth; Fangyi Zhao; Sorsaburu, Sebastian; Stefaniak, Victoria J.; Corya, Sara A. // BMC Psychiatry;2010, Vol. 10, p43 

    Background: An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation...

  • Olanzapine: warning of neutropenia.  // WHO Drug Information;1999, Vol. 13 Issue 3, p171 

    Reports that the Australian Adverse Drug Reactions Advisory Committee has received reports related to the antipsychotic agent, olanzapine. Most frequent adverse reactions; Prescribers' need to be aware that white cell disorders, seizures and neuroleptic malignant syndrome can all occur in...

  • Zyprexa Relprevv Receives Attention After 2 Unexplained Deaths.  // Journal of Psychosocial Nursing & Mental Health Services;Aug2013, Vol. 51 Issue 8, p5 

    No abstract available.

  • Diabetic Ketoacidosis With Olanzapine Treatment. Gatta, Blandine; Rigalleau, Vincent; Gin, Henri // Diabetes Care;Jun99, Vol. 22 Issue 6, p1002 

    Reports on a case of diabetic ketoacidosis that was treated with olanzopine, an antipsychotic drug. Adverse effects of olanzopine; Background on the case; Comparison of olanzapine and clozapine.

  • Adverse Reaction Research.  // Reactions Weekly;8/8/2009, Issue 1264, p4 

    The article discusses research being done on olanzapine long-acting injection. It references the study " Post-Injection Delirium/Sedation Syndrome Observed With Olanzapine Long-Acting Injection," by D. McDonnell presented at the 9th World Congress of Biological Psychiatry. The study suggested...

  • Olanzapine.  // Reactions Weekly;2/13/2010, Issue 1288, p30 

    The article describes the case of a 23-year-old man who experienced while undergoing treatment with olanzapine.

  • Olanzapine.  // Reactions Weekly;Jun2014, Vol. 1504 Issue 1, p21 

    An abstract of the article "Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: A new syndrome in emergency psychiatry," by K. Buts and colleagues is presented.

  • The potential role of appetite in predicting weight changes during treatment with olanzapine. Case, Michael; Treuer, Tamas; Karagianis, Jamie; Hoffmann, Vicki Poole // BMC Psychiatry;2010, Vol. 10, p72 

    Background: Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite. Methods: Data were used from adult patients for whom both...

  • Blood lactate levels in patients receiving first- or second- generation antipsychotics. Glavina, Trpimir; Mrass, Damir; Dodig, Tajana; Glavina, Gordana; Pranić, Shelly; Uglešić, Boran // Croatian Medical Journal;Feb2011, Vol. 52 Issue 1, p41 

    Aim To compare the blood lactate levels between patients with psychotic disorder receiving first- and those receiving second-generation antipsychotics. Methods The study was conducted at the psychiatric inpatient and outpatient clinics of the Split Clinical Hospital from June 6,2008 to October...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics